A detailed history of Ray Dalio (Bridgewater Associates, LP) transactions in Abb Vie Inc. stock. As of the latest transaction made, Bridgewater Associates, LP holds 204,572 shares of ABBV stock, worth $36.2 Million. This represents 0.23% of its overall portfolio holdings.

Number of Shares
204,572
Previous 288,525 29.1%
Holding current value
$36.2 Million
Previous $49.5 Million 18.37%
% of portfolio
0.23%
Previous 0.26%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$163.84 - $199.33 $13.8 Million - $16.7 Million
-83,953 Reduced 29.1%
204,572 $40.4 Million
Q2 2024

Aug 14, 2024

SELL
$154.79 - $180.76 $25 Million - $29.1 Million
-161,254 Reduced 35.85%
288,525 $49.5 Million
Q1 2024

May 14, 2024

SELL
$159.82 - $182.1 $25.1 Million - $28.6 Million
-157,114 Reduced 25.89%
449,779 $81.9 Million
Q4 2023

Feb 14, 2024

BUY
$137.6 - $154.97 $4.26 Million - $4.79 Million
30,933 Added 5.37%
606,893 $94.1 Million
Q3 2023

Nov 13, 2023

SELL
$133.59 - $154.65 $7.79 Million - $9.02 Million
-58,345 Reduced 9.2%
575,960 $85.9 Million
Q2 2023

Aug 11, 2023

BUY
$132.51 - $164.9 $29.5 Million - $36.8 Million
222,875 Added 54.17%
634,305 $85.5 Million
Q1 2023

May 12, 2023

BUY
$144.61 - $166.54 $55.1 Million - $63.5 Million
381,328 Added 1266.79%
411,430 $65.6 Million
Q4 2022

Feb 13, 2023

SELL
$138.31 - $165.87 $25.3 Million - $30.3 Million
-182,648 Reduced 85.85%
30,102 $4.87 Million
Q3 2022

Nov 10, 2022

BUY
$134.21 - $153.93 $17.6 Million - $20.1 Million
130,900 Added 159.93%
212,750 $28.6 Million
Q2 2022

Aug 11, 2022

BUY
$137.62 - $174.96 $871,685 - $1.11 Million
6,334 Added 8.39%
81,850 $12.5 Million
Q1 2022

May 13, 2022

BUY
$131.98 - $163.75 $4.44 Million - $5.51 Million
33,661 Added 80.42%
75,516 $12.2 Million
Q4 2021

Feb 14, 2022

SELL
$107.43 - $135.93 $3.57 Million - $4.52 Million
-33,241 Reduced 44.26%
41,855 $5.67 Million
Q3 2021

Nov 12, 2021

BUY
$106.4 - $120.78 $2.39 Million - $2.72 Million
22,491 Added 42.75%
75,096 $8.1 Million
Q2 2021

Aug 13, 2021

BUY
$105.21 - $117.21 $5.53 Million - $6.17 Million
52,605 New
52,605 $5.93 Million
Q1 2021

May 14, 2021

SELL
$102.3 - $112.62 $2.59 Million - $2.85 Million
-25,294 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$80.49 - $108.67 $2.04 Million - $2.75 Million
25,294 New
25,294 $2.71 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $313B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track Ray Dalio's Portfolio

Track Ray Dalio Portfolio

Follow Ray Dalio (Bridgewater Associates, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgewater Associates, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bridgewater Associates, LP and Ray Dalio with notifications on news.